These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 13432604

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Trials of treatment by p-(di-2-chloroethylamino)phenylbutyric acid in Hodgkin's disease, chronic lymphoid leukemia and different sarcomas of lymphatic tissue; study of one hundred cases].
    BERNARD J, MATHE G, WEIL M.
    Rev Fr Etud Clin Biol; 1956 Dec; 1(10):1121-32. PubMed ID: 13408766
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of the resistant stages of Hodgkin's disease and lymphoblastic diseases.
    HOCHMAN A, ICKOWICZ M.
    Br J Radiol; 1954 Aug; 27(320):467-9. PubMed ID: 13182191
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical experience with CB 1348 (NN-di(2-chloroethyl, -P-aminophenylbutyric acid) in the treatment of chronic lymphatic leukaemia.
    HANSEN PB.
    Acta Radiol (Stockh); 1957 Mar; 47(3):210-16. PubMed ID: 13424344
    [No Abstract] [Full Text] [Related]

  • 10. Early experience with p-(N, N-di-2-chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemia.
    ALTMAN SJ, HAUT A, CARTWRIGHT GE, WINTROBE MM.
    Cancer; 1956 Mar; 9(3):512-7. PubMed ID: 13330000
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Triethylene melamine (TEM) in the treatment of malignant lymphoid disease.
    HAMBLY CK, ROBERTSON TI.
    Med J Aust; 1955 Jun 18; 42(1 25):900-11. PubMed ID: 13243982
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of malignant lymphomas and lymphadenoses with leukeran.
    LIBANSKY J, CHUDOMEL V, BRABEC V, SOCHMAN J.
    Neoplasma; 1959 Jun 18; 6():415-24. PubMed ID: 14416684
    [No Abstract] [Full Text] [Related]

  • 15. [The use of nitrogen mustard in the treatment of lymphatic diseases of a malignant type].
    RABENKO J, CORREA URQUIZA LM.
    Prensa Med Argent; 1959 Oct 09; 46():2549-54. PubMed ID: 14435621
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A comparative study of the effectiveness of HN2 and cyclophosphamide in bronchogenic carcinoma, Hodgkin's disease and lymphosarcoma.
    SPEAR PW, PATNO ME.
    Cancer Chemother Rep; 1962 Feb 09; 16():413-5. PubMed ID: 13915594
    [No Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of the effect of degranol.
    SANDOR L, CERNY V, UJHAZY V, WINKLER A.
    Neoplasma; 1959 Feb 09; 6():179-82. PubMed ID: 14441442
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.